Cloudflare stock rose on Q4 earnings and revenue that topped Wall Street targets while full-year 2025 revenue guidance met ...
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback